People are paying for the research no one else will compile.
"We finished radiation and started Temodar. The neuro-oncologist is great but every appointment is 15 minutes and we leave with a printed handout that says nothing. The trials list on clinicaltrials.gov is 400 entries long. I just wanted someone to read it all and tell me which ones he could actually qualify for."
— Daniel, caregiver to his brother (GBM, IDH-wildtype)
"We're MGMT-unmethylated. I keep reading that this changes the calculus on Temodar but no one will tell me what to ask about. We've already started a GoFundMe for whatever experimental thing comes next — I just need to know which experimental thing is actually worth chasing."
— Priya, caregiver to her father
This is for Daniel. And Priya. And every family that has spent a Saturday night scrolling clinicaltrials.gov because the appointments are too short.
What you'll get back
Sample findings from a brief like yours. Each rated by how many specialists converged on the evidence.
Promising
Tumor-Treating Fields (Optune) — Adherence & Real-World Outcomes
Optune (TTFields) added to maintenance temozolomide showed an OS benefit in the EF-14 trial. Real-world data confirms the survival signal but is highly adherence-dependent — patients wearing the device >18 hours/day see substantially better outcomes. Practical adherence support, scalp care, and skin protocols are well-described in the published literature but rarely covered in the initial consult.
Question to bring to your neuro-oncologist: if we're considering Optune, what adherence support and skin-care protocols do you recommend, and what's the threshold of daily wear we should target?
Emerging
Repurposed Agents — Metformin, Disulfiram, Mebendazole
Several repurposed agents have published preclinical and early-clinical signals in glioblastoma: metformin (mTOR/AMPK), disulfiram + copper (proteasome inhibition, blood-brain barrier penetrant), and mebendazole (tubulin disruption, BBB penetrant). Most are in early-phase trials. Safety profiles are well-established, though disulfiram has known interactions to flag.
Question to bring to your neuro-oncologist: are any of these repurposed agents reasonable to discuss adding alongside standard temozolomide given my MGMT and IDH status?
Emerging
Metabolic Approaches — Ketogenic Therapy & Glucose Management
Ketogenic diet and calorie restriction in GBM have a growing body of small clinical trials and case series. The mechanism (Warburg metabolism, glucose dependency) is biologically plausible and well-characterized. Effect sizes on survival are unclear but quality-of-life and seizure-burden data is encouraging in adherent patients.
Question to bring to your neuro-oncologist: would a structured ketogenic protocol with metabolic monitoring be reasonable alongside standard care, and can you coordinate with a registered dietitian?
Sample findings shown are representative of the structure your brief will follow. Yours is tailored to the specific question you submit.
Why $99
At a top academic center — Mayo Clinic, MD Anderson, Cleveland Clinic — your case might be reviewed by 5-7 sub-specialists in a tumor board. That access takes weeks of referrals, often travel, and runs $2,000–$5,000 just for the consult.
Insight Swarm convenes 14 specialist agents for your case. Same shape of analysis. 48 hours instead of 6 weeks. $99 instead of $5,000+.